Are the European Practice Guidelines for the Management of Arterial Hypertension (2007) adapted to the old and the frail? Anette Hylen

Slides:



Advertisements
Similar presentations
JNC 8 Guidelines….
Advertisements

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.
Valsartan Antihypertensive Long-Term Use Evaluation Results
ASCOT TRIAL Abbas Zaidi 20/09/05. Hypertension is one of the most prevalent risk factors for cardiovascular disease, affecting as many as 800 million.
The INSIGHT study - Reliable blood pressure control and additional benefits for hypertensive patients Anthony M Heagerty Department of Medicine Manchester.
Overcoming the challenge of blood pressure control in prediabetic and diabetic patients: PICASSO T2D Study Efficacy and tolerability of fixed dose combination.
Treatment of Hypertension in Patients over the age of 80 Debra Bynum, MD Associate Professor Division of Geriatric Medicine.
Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Pharmacological Treatment of Hypertension Update 2012.
Hypertension and The Older Patient
Hypertension in the Elderly
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
Is It the Achieved Blood Pressure or Specific Medications that Make a Difference in Outcome, or Is the Question Moot? William C. Cushman, MD Professor,
Hypertension In elderly population. JNC VII BP Classification SBP mmHgDBP mmHg Normal
Systolic hypertension not an isolated problem Michael Weber, MD Professor of Medicine Associate Dean Downstate College of Medicine State University of.
Blood pressure control in primary health care WORKSHOP
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Hypertension in the Elderly - Its Different From in the Young From in the Young Physiology Physiology HYVET Trial Results HYVET Trial Results Managing.
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.
Hypertension Dr Nidhi Bhargava 8/10/13. Why Treat Increased risk of cardiovascular death and mortality Increased systolic, diastolic and pulse pressures.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
HYPERTENSION RECOMMENDATIONS FOR FOLLOW UP BASED ON INITIAL BP READING
Polypill x Aspirin Project Groups 3 and 4
Objective: To asses the efficacy of hydrochlorothiazide on 24-h blood pressure (BP) control.Methods: Review of all the randomized trials that assessed.
Baseline characteristics. Patient flow Completed Completed Perindopril Placebo Randomised Not randomised Registered.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
VBWG Growth in heart disease, 2000–2050 Deaths Population Foot DK et al. J Am Coll Cardiol. 2000;35:
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
1 ALLHAT Antihypertensive Trial Results by Baseline Diabetic Status January 28, 2004.
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
2007 Hypertension as a Public Health Risk January, 2007.
Treatment of Hypertension in Adults With Diabetes DR AMAL HARFOUSH.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
Kelsey Vonderheide, PA1.  Heart Failure—a large number of conditions affecting the structure and function of the heart that make it difficult for the.
Results from ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm VBWG.
1 Effect of Ramipril on the Incidence of Diabetes The DREAM Trial Investigators N Engl J Med 2006;355 FM R1 윤나리.
CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
Antonio Coca, MD, PhD, FRCP, FESC
An analysis of 22,672 patients from the CLARIFY registry
Blood Pressure and Lipid Trials: Rationale, Importance and Design
Alcohol, Other Drugs, and Health: Current Evidence July–August 2017
The SPRINT Research Group
Hypertension in the Post SPRINT era
Hypertension JNC VIII Guidelines.
Blood Pressure and Age in Controlling Hypertension
Health and Human Services National Heart, Lung, and Blood Institute
United States Preventive Services Task Force: Recommendations for ABPM
The Anglo Scandinavian Cardiac Outcomes Trial
Teaching Tool: Blood Pressure Classification
Systolic Blood Pressure Intervention Trial (SPRINT)
Progress and Promise in RAAS Blockade
The following slides highlight a report on a presentation at the Late-breaking Trials Session and a Satellite Symposium of the American Heart Association.
The Hypertension in the Very Elderly Trial (HYVET)
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Table of Contents Why Do We Treat Hypertension? Recommendation 5
The following slides highlight a report by Dr
Presentation transcript:

Are the European Practice Guidelines for the Management of Arterial Hypertension (2007) adapted to the old and the frail? Anette Hylen MD PhD, Medical Department, Diakonhjemmets Hospital, Oslo Kavli’s Research Centre for Ageing and Dementia, Bergen GerIT

Hypertension – mainly a risk factor, not responsible for symptoms When should it be treated and how – in the old and the frail ? Risk factor for:  Stroke (1 SD SBP: RR 1.59) Rotterdam studien, Mattace-Raso FU, JAGS 2004  Myocardial Infarction (1 SD SBP: RR 1.24) Rotterdam studien, JAGS  Cardiac failure (LVH and post infraction)  Renal failure (hypertensive renal disease)  Dementia (Vascular and Alzheimer) – but when dementia is progressing BP is falling Skoog I 2001

Hypertension in the old and the frail: Still few studies which include patients 85+ years The study patients are mainly robust elderly with low comorbidity A high proportion of the 80+ patients are frail and with a high comorbidity. Heterogenity in elderly patients (age, comorbidity, function) Life expectancy is high - and increasing

What we need to know: How to assess the patients: measure BP, other assessment BP limits according to risk Indications for drug treatment What drugs? Treatment goals

Sub-group analyses - meta-analyse > 80 yrs, N=1670 RCT Gueyffier F. Bulpitt C. et al, Lancet % risk reduction for stroke NNT 1 per 100 patients treated one year 22 % risk reduction for myocardial infarction 39 % risk reduction fro cardiac failure No risk reduction for cardiovascular death or total death

3845 patients from Europe, China, Australasia, and Tunisia who were 80 years of age or older and had a sustained systolic blood pressure of 160 mm Hg or more to receive either the diuretic indapamide (sustained release, 1.5 mg) or matching placebo. The angiotensin-converting-enzyme inhibitor perindopril (2 or 4 mg), or matching placebo, was added if necessary to achieve the target blood pressure of 150/80 mm Hg. The primary end point was fatal or nonfatal stroke. At 2 years, the mean blood pressure while sitting was 15.0/6.1 mm Hg lower in the active-treatment group than in the placebo group. 30% reduction in the rate of fatal or nonfatal stroke (95% confidence interval [CI], -1 to 51; P=0.06) 39% reduction in the rate of death from stroke (95% CI, 1 to 62; P=0.05) 21% reduction in the rate of death from any cause (95% CI, 4 to 35; P=0.02) 23% reduction in the rate of death from cardiovascular causes (95% CI, -1 to 40; P=0.06) 64% reduction in the rate of heart failure (95% CI, 42 to 78; P<0.001). Fewer serious adverse events were reported in the active-treatment group (358, vs. 448 in the placebo group; P=0.001). CONCLUSIONS: The results provide evidence that antihypertensive treatment with indapamide (sustained release), with or without perindopril, in persons 80 years of age or older is beneficial. Beckett et al. N May 2008

“Elderly” is mentioned 12 times

Independent of age

In the largest meta-analysis of observational data available today (61 studies in almost 1million subjects without overt cardiovascular disease, 70% europeans Lancet 2002 : Both systolic and diastolic blood pressures were independently and similarly predictive of stroke and coronary mortality, and the contribution of pulse pressure was small, particularly in individuals aged less than 55 years. By contrast, in middle aged and elderly hypertensive patients with cardiovascular risk factors or associated clinical conditions, pulse pressure showed a strong predictive value for cardiovascular events. Systolic vs diastolic and pulse pressure

”All patients should be classified not only in relation to the grades of hypertension but also in terms of the total cardiovascular risk resulting from the coexistence of different risk factors, organ damage and disease.”

AGE > 55 years in Men and 65 years in female is a risk factor (Organ damage)

Conclusions Treatment of SH in older patients with SBP of at least 160 mmHg is supported by strong evidences. The evidence available to support treatment of patients to the level of 140 mmHg or those with baseline SBP of 140 to 159 mmHg is less strong; thus, this treatment decisions should be more sensitive to patient preferences and tolerance of therapy.

Blood Pressure and Survival in the Oldest Old Journal of the American Geriatrics Society 2007, 55 (3), 383–388. Oates DJ et al. In a cohort of very old (80+yrs), hypertensive veterans, in subjects with controlled BPs (<140/90), subjects with lower BP levels had a lower 5-year survival than those with higher BPs. This suggests that clinicians should use caution in their approach to BP lowering in this age group. All patients were controlled to < 140/90 – but don’t push it too far….. Treatment goals

Diagnostic procedures aim at: 1)establishing blood pressure levels 2)identifying secondary causes of hypertension 3)evaluating the overall cardiovascular risk by searching for other risk factors, target organ damage and concomitant diseases or accompanying clinical conditions. The diagnostic procedures comprise: repeated blood pressure measurements medical history physical examination laboratory and instrumental investigations Diagnostic evaluation

Premorbid status RobustIntermediate Minor functional imp. Substantial Functional imp. Dependent Comorbidity Life expectancy illness/risk factor outcome HYPERTENSION

When to initiate antihypertensive treatment?

Drug treatment in the elderly Guide by comorbidity –Coronary syndrom: Beta-blocker –Atrial fibrillation in need of reduction of frequency: Beta-blocker –Cardiac failure: ACE-inhibitor or/and beta-blocker, event AII blocker –COPD: Avoid non-selective beta-blockers Start low - go slow Rather two or more drugs in combination than one in high dose Remember to check: electrolytes, creatinin when using ACEI, ARB and diuretics OBS drug interactions Follow up for antihypertensive drug treatment in elderly patients is crucial

To achieve maximum reduction in the long-term total risk of cardiovascular disease. Treatment of the raised BP per se as well as of all associated reversible risk factors. BP should be reduced to at least below 140/90 mmHg. Target BP should be at least 130/80 mmHg in diabetics and in high or very high risk patients. Despite use of combination treatment, reducing systolic BP to 140 mmHg may be difficult. Additional difficulties should be expected in elderly and diabetic patients, and, in general, in patients with cardiovascular damage. In order to more easily achieve goal BP, antihypertensive treatment should be initiated before significant cardiovascular damage develops. Treatment goals

Blood Pressure and Survival in the Oldest Old Journal of the American Geriatrics Society 2007, 55 (3), 383–388. Oates DJ et al. In a cohort of very old (80+yrs), hypertensive veterans, in subjects with controlled BPs (<140/90), subjects with lower BP levels had a lower 5-year survival than those with higher BPs. This suggests that clinicians should use caution in their approach to BP lowering in this age group. All patients were controlled to < 140/90 – but don’t push it too far….. Treatment goals

Conclusions Definitions and classification of BP levels are now independent of age Total cardiovascular risk should decide wether treatment should be given BP in supine posistiton after 1 and 5 mins – and 24 hrs BT are recommended in elderly persons Evidence for benefit of antihypertensive treatment in subjects >80 years with sustained systolic BP >160 mmhg is present! The 2007 guidelines focus particularly on elderly - and correspond better to ”best practice” in geriatric medicine than previous guidelines